The brain may be about to have its Ozempic moment

Drugmakers are betting that orexins, peptides that regulate wakefulness, could become the next blockbuster class after GLP-1 drugs like Ozempic. Just as GLP-1 revolutionized weight loss, orexin-based treatments might transform the management of sleep and neurological disorders. The Economist explores the science and the commercial potential.